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Context: High dietary salt intake is known to aggravate arterial hypertension. This effect could 
be of particular relevance in the setting of primary aldosteronism (PA), which is associated 
with cardiovascular damage independent of blood pressure levels. The aim of this study was to 
determine the impact of therapy on salt intake in PA patients.
Patients and Methods: A total of 148 consecutive PA patients (66 with unilateral and 82 with 
bilateral PA) from the database of the German Conn’s Registry were included. Salt intake was 
quantified by 24-hour urinary sodium excretion before and after initiation of PA treatment.
Study design: Observational longitudinal cohort study.
Setting: Tertiary care hospital.
Results: At baseline, unilateral PA patients had a significantly higher urinary sodium excretion 
than patients with bilateral disease (205 vs 178 mmol/d, P = 0.047). Higher urinary sodium 
excretion correlated with an increased cardiovascular risk profile including proteinuria, impaired 
lipid, and glucose metabolism and was associated with higher daily doses of antihypertensive 
drugs to achieve blood pressure control. In unilateral disease, urinary sodium excretion dropped 
spontaneously to 176 mmol/d (P = 0.012) 1 year after unilateral adrenalectomy and remained 
low at 3 years of follow-up (174 mmol/d). In contrast, treatment with mineralocorticoid receptor 
antagonists (MRA) in bilateral PA patients was not associated with a significant change in 
urinary sodium excretion at follow-up (179 mmol/d vs 183 mmol/d).
Conclusion: PA patients consuming a high-salt diet, estimated based on urinary sodium 
excretion, respond to adrenalectomy with a significant reduction of salt intake, in contrast to 
MRA treatment. (J Clin Endocrinol Metab 105: e484–e493, 2020)
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The triumph of sodium chloride (salt) began in the age of ancient Babylonia and Egypt, where salt was al-
ready used in the preservation of food. As a symbol of the 
importance of salt, Roman soldiers received their salary, 
derived from the Latin word salarium (salt), in part as salt 
itself. Nowadays, salt remains an important spice and pre-
servative and very popular especially as part of Western 
diet. However, high salt intake has undesirable health ef-
fects and is regarded as an independent cardiovascular 
risk factor. Beside its negative impact on left ventricular 
mass and arterial stiffness, high salt intake results in an 
elevated risk of stroke and cardiovascular disease as well 
as an increase of blood pressure (1–4). For this reason, re-
nunciation of salt intake is a common and effective public 
health approach of lowering blood pressure, with an even 
more distinct impact in resistant hypertension (5–8).
One of the main regulators of salt and water balance is 
the steroid hormone aldosterone, which is synthesized in 
the zona glomerulosa of the adrenal cortex and is stimu-
lated by increased renin and angiotensin II plasma levels. 
Aldosterone acts predominantly via the epithelial sodium 
channel (ENaC) in the distal nephron leading to increased 
sodium reabsorption and loss of potassium. Primary al-
dosteronism (PA) is characterized by excessive secretion 
of aldosterone despite suppressed renin levels. It affects 
5% to 10% of patients with high blood pressure and is 
the most frequent cause of endocrine hypertension (9, 10). 
Aldosterone excess in PA leads to hypervolemia by so-
dium and water retention and causes target organ damage 
through pro-inflammatory and pro-fibrotic effects, even 
independent of blood pressure changes (11, 12).
A recent study showed that reducing dietary salt in-
take in PA patients results in a substantial reduction of 
left ventricular mass index and therefore is of clinical 
relevance (13). Although many experimental studies have 
indicated that inadequately high salt intake together with 
aldosterone excess is deleterious for target organ damage, 
data about salt intake especially after initiation of treat-
ment in PA patients are very limited (13, 14).
It was the objective of this study to investigate 
long-term intake of salt in a large cohort of PA patients 
and to analyze its association with treatment—uni-
lateral adrenalectomy or mineralocorticoid receptor 
blockade by spironolactone. It was our hypothesis that 
PA is associated with high sodium consumption and 
that remission from excessive aldosterone levels and 
action (mineralocorticoid receptor antagonist [MRA] 
treatment) might positively affect salt intake.
Methods
From 2008 to 2015, we prospectively enrolled 323 patients 
with PA in the Munich center of the German Conn’s Registry. 
For the present study, we selected patients fulfilling the fol-
lowing criteria: confirmed PA treated by either adrenalectomy 
(ADX) in unilateral PA or MRA in bilateral PA and 24-hour 
urinary sodium excretion measurement at baseline, and 1 and 
3 years after initiation of specific PA directed treatment, re-
spectively. Patients with urine volume <500  mL/d were ex-
cluded to ensure completeness of 24-hour urine collection. 
We identified 148 patients fulfilling the inclusion criteria; they 
became our study cohort. All patients gave written informed 
consent, and the protocol of the German Conn’s Registry was 
approved by the ethics committee of the University of Munich.
At time of diagnosis and at each visit, patients underwent 
standard procedures including collection of anthropometric 
data, clinical characteristics, current medication, and labora-
tory testing. Blood pressure was measured using an automated 
device over 24 hours. To estimate daily salt intake, the patients 
conducted a 24-hour urine collection at baseline after adjust-
ment of medication for further testing of PA to determine 
urinary sodium excretion at each visit.
For diagnosis of PA, patients underwent standardised 
testing, which was performed according to Endocrine Society 
Practice Guidelines (10). The diagnosis of PA was confirmed 
by an elevated plasma aldosterone to renin ratio (cutoff 
12.0 ng/U, sitting position) followed by an abnormal con-
firmatory test (ie, salt loading test, captopril challenge test, or 
both). Computed tomography scanning in combination with 
adrenal vein sampling was used for subtype diagnosis, as de-
scribed elsewhere (15). In 7.4% of the patients, blood pressure 
medication was stopped, whereas in the remaining patients, 
alpha 1-adrenergic receptor (doxazosin) or calcium-channel 
blockers (verapamil) replaced medication. ADX was offered 
to all patients with unilateral PA. Patients with unilateral PA 
who did not undergo ADX were not included in the study. 
All patients with bilateral PA were treated with MRAs using 
spironolactone with a starting dose of 25 to 50 mg/d in the 
majority of cases. Reevaluation at follow-up followed a stand-
ardized protocol.
Genotyping for KCNJ5, ATP1A1, ATP2B3, and CACNA1D 
was performed in surgically resected tumor tissue of unilateral 
PA as described elsewhere (16).
Statistical analysis
All values are expressed as median, 25th and 75th per-
centile, if not mentioned otherwise. Body mass index (BMI) 
was calculated as weight in kilograms divided by the square 
of the height in meters. Data between groups were compared 
using Mann-Whitney U test or Kruskal-Wallis test, respect-
ively. Within-group changes from baseline to follow-up were 
calculated by Wilcoxon signed-rank test. Spearman’s rank 
order was used to perform bivariate correlation analysis. 
Stepwise multiple regression analysis was performed for 
multivariate analysis. Two-tailed probability values <5% were 
considered to be statistically significant. Statistical analysis 
was done using standard statistical software (SPSS 25, IBM, 
Chicago, IL).
Results
Clinical and biochemical characteristics of all patients 
are summarized in Table 1. In total, 38% of patients 
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(n  =  56) were female. Patients had a median age of 
51 years, were overweight with a BMI of 27.4 kg/m2, 
and had low potassium and high aldosterone levels, 
as expected. Twenty-four-hour systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) was elevated 
with 144/93 mm Hg despite receiving a median of 2.5 
doses of antihypertensive drugs per day (DDD). Median 
urinary sodium excretion was 184 mmol/d, reflecting a 
daily salt consumption of more than 10 g, which is more 
than twice of the amount recommended by the World 
Health Organization (17).
There was no significant difference according to age, 
sex, BMI, or blood pressure in bilateral versus unilateral 
PA (Table 2). Unilateral PA patients had lower potas-
sium (P < 0.001) and higher plasma aldosterone values 
(P  <  0.001) as well as higher 24-hour urinary potas-
sium excretion (105 mmol/d vs 80 mmol/d; P < 0.001), 
as expected. Patients with unilateral PA had higher pro 
b-type natriuretic peptide (110 pg/mL vs 78 pg/mL; 
P = 0.013) and urinary sodium excretion (205 mmol/d 
vs 178 mmol/d; P = 0.047).
Patients were treated by ADX and MRA according to 
adrenal vein sampling results, respectively, and under-
went reassessment of salt intake 1  year after start of 
treatment. Serum potassium levels normalized in both 
subgroups and urinary potassium excretion, blood 
pressure, proteinuria, and pro b-type natriuretic pep-
tide were significantly reduced (Tables 1 and 2). In 
patients with unilateral PA, there was a significant de-
crease in aldosterone levels and urinary sodium excre-
tion (P < 0.001; P = 0.012) after ADX, which was not 
the case in patients with bilateral disease treated with 
MRA. This drop was maintained at 3 years in unilat-
eral PA, whereas sodium excretion remained high in bi-
lateral disease (Fig. 1). Despite these changes, 95% of 
patients (n = 141) remained at an estimated salt intake 
above the recommended limit.
Higher sodium excretion at baseline was predomin-
antly found in males and correlated with features of the 
metabolic syndrome including overweight, large waist 
circumference, and dyslipidemia. In addition, higher 
sodium excretion was accompanied by higher 24-hour 
SBP and 24-hour DBP despite intake of a higher number 
of antihypertensive drugs (Fig. 2 and Table 3).
Moreover, we detected significantly lower sodium 
excretion in APA patients showing KCNJ5 mutation 
compared with patients with a wild-type genotype in 
baseline univariate analysis (161 mmol/d vs 228 mmol/d; 
P  = 0.008). After adjustment for sex, because KCNJ5 
mutation is found more frequently in females (in our 
Table 1. Baseline, 1-, and 3-Year Follow-up Characteristics of All Patients With Primary Aldosteronism
Patient Characteristics (n = 148) No. Baseline After 1 Y P After 3 Y P
Sex, F/M 148 56/92 -- NC -- NC
Age, y 148 51 [45; 59] -- NC -- NC
BMI, kg/m2 148 27.4 [24.3; 31.2] 27.4 [24.0; 30.5] 0.332 27.8 [24.5; 30.5] 0.339
Aldosterone, ng/L 148 170 [107; 263] 129 [59; 239] 0.109 155 [83; 279] 0.986
Plasma renin, mU/L 148 4.1 [2.1; 8.5] 16.0 [6.6; 28.1] <0.001 19.6 [7.2; 39.9] <0.001
SBP, mm Hg 148 150 [137; 166] 133 [123; 143] <0.001 131 [121; 141] <0.001
DBP, mm Hg 148 93 [84; 102] 87 [80; 93] <0.001 86 [79; 93] <0.001
24-h SBP, mm Hg 114 144 [137; 154] 132 [123; 139] <0.001 130 [121; 138] <0.001
24-h DBP, mm Hg 114 93 [83; 99] 82 [76; 87] <0.001 82 [77; 87] <0.001
DDD, n 148 2.5 [1.0; 4.0] 1.7 [0.5; 3.6] 0.004 1.7 [0.5; 3.0] <0.001
Serum sodium, mmol/L 148 141 [139; 142] 139 [137; 140] <0.001 140 [138; 141] 0.001
Serum potassium, mmol/L 148 3.5 [3.2; 3.8] 4.1 [3.9; 4.4] <0.001 4.4 [4.1; 4.6] <0.001
Serum creatinine, mg/dL 148 0.9 [0.7; 1.0] 1.0 [0.8; 1.2] <0.001 1.0 [0.9; 1.2] <0.001
GFR, mL/min/1.73 m2 148 85 [72; 100] 73 [59; 84] <0.001 69 [58; 81] <0.001
HDL-C, mg/dL 148 56 [45; 69] 50 [41; 64] <0.001 53 [44; 64] <0.001
LDL-C, mg/dL 148 120 [98; 148] 121 [95; 143] 0.448 119 [85; 143] 0.603
Triglycerides, mg/dL 148 95 [67; 135] 119 [82; 175] <0.001 120 [83; 177] <0.001
Total cholesterol, mg/dL 148 193 [173; 221] 191 [168; 223] 0.807 191 [163; 224] 0.859
FPG, mg/dL 148 98 [91; 110] 99 [91; 106] 0.139 99 [92; 109] 0.197
HbA1c, % 130 5.3 [5.1; 5.7] 5.5 [5.2; 5.8] <0.001 5.4 [5.2; 5.8] <0.001
proBNP, pg/mL 137 86 [52; 185] 52 [29; 93] <0.001 47 [26; 120] <0.001
Proteinuria, mg/d 148 143 [109; 210] 104 [83; 126] <0.001 112 [85; 134] <0.001
24-h urinary potassium, mmol/d 148 87 [67; 125] 68 [52; 87] <0.001 69 [49; 84] <0.001
24-h urinary sodium, mmol/d 148 184 [146; 253] 177 [128; 238] 0.027 182 [136; 240] 0.126
Estimated salt intake, g/d 148 10.8 [8.5; 14.8] 10.4 [7.5; 13.9] 0.027 10.6 [8.0; 14.0] 0.126
Data are given as median, and 25th and 75th percentile in square brackets. Significance is marked in bold. Comparisons to baseline values were 
performed by Wilcoxon signed-rank test.
Abbreviations: 24-h DBP, 24-hour diastolic blood pressure; 24-h SBP, 24-hour systolic blood pressure; DBP, diastolic blood pressure; DDD, defined 
daily doses of antihypertensive medication; FPG, fasting plasma glucose; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; 
LDL-C, low-density lipoprotein cholesterol; NC, not calculated; proBNP, pro b-type natriuretic peptide; SBP, systolic blood pressure.
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study, 73% females), these differences disappeared, in 
line with a sex-related influence of salt intake rather 
than a specific genetic impact of the KCNJ5 mutation 
(Fig. 2 and Table 3).
Proteinuria was another factor closely linked with 
high salt intake both at baseline and at after-care visits 
(Table 3). In this context, a reduction of urinary sodium 
excretion after initiation of treatment was accompanied 
by a decline in proteinuria at 1- (r = 0.278; P = 0.001) as 
well as 3-year (r = 0.242; P = 0.003) follow-up (Fig. 3).
After initiation of treatment of PA urinary sodium 
excretion still correlated with parameters of metabolic 
syndrome including dyslipidemia, higher fasting plasma 
glucose, hemoglobin A1c, and BMI (Table 3). Similarly, 
DDDs were strongly correlated with urinary sodium ex-
cretion both at 1- (r = 0.213; P = 0.009) and 3-year re-
assessment (r = 0.379; P < 0.001).
Over time, we recorded 15 cardiovascular events in 
our patients. Dividing the total cohort symmetrically 
into low and high urinary sodium excretion according 
to baseline values, we observed 10 cardiovascular 
events in the high sodium group, but only 5 in the low 
sodium group (P = NS). Taking into account the average 
sodium excretion from baseline to 3-year follow-up, 11 
of 15 cardiovascular events occurred in the high-sodium 
group.
Discussion
PA is attracting attention as the most frequent form of 
endocrine hypertension. High aldosterone levels per se 
are not regarded as a cardiovascular risk factor, as seen 
in indigenous people in New Guinea with chronic salt 
deficiency and consecutive secondary aldosteronism 
(18). However, in PA aldosterone levels are elevated in-
appropriately for salt status, resulting in target organ 
damage independent of blood pressure levels. Potential 
mechanisms involved are detailed in a recent report by 
Funder (19).
To our knowledge, this is the first study to evaluate 
spontaneous salt intake, as estimated by urinary so-
dium excretion, in long-term follow-up in unilateral 
and bilateral PA patients. At baseline, urinary sodium 
excretion in both subgroups was much higher than re-
commended by the World Health Organization and 
higher than in population-based studies in Germany. 
Assuming that the sodium excreted in urine arose from 
diet, estimated median daily salt intake was 11.9 g in 
men and 9.4  g in women, which tends to be slightly 
higher than the German median of 10.0 g/d in men and 
8.4 g/d in women (20). Thereby 64% of our PA patients 
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Salt intake itself is a well-known risk factor for hyper-
tension but also for cardiovascular disease (1–4, 21–23). 
In a Finnish study, it has been shown that an increase of 
daily salt intake of 100 mmol (~5.8 g salt) is associated 
with an increase of cardiovascular events of 45% over 
a 7-year follow-up and predicted mortality in over-
weight men (24). High sodium intake is associated with 
higher risk for stroke, independent of blood pressure 
Figure 2. Correlation of 24-hour systolic blood pressure with 24-hour urinary sodium excretion at baseline.
*Patients carrying KCNJ5 mutation. The dashed line marks an estimated salt intake of 5 g/d as recommended by the World Health Organization. 
Abbreviation: 24-h SBP, 24-hour systolic blood pressure.
Figure 1. Twenty-four-hour urinary sodium excretion at baseline and at 1- and 3-year follow-up in unilateral and bilateral primary aldosteronism.
Median and 95% confidence interval are shown. *Significance. Abbreviation: PA, primary aldosteronism.
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changes (25). Moreover, salt restriction has been dem-
onstrated to improve blood pressure–lowering effects 
of antihypertensive drugs (26). In patients with arterial 
hypertension or metabolic syndrome blood pressure–
lowering effects of low-salt diet are even more distinct 
than in normotensives, with a decrease of 23 mm Hg 
in systolic and 9  mm Hg in diastolic blood pressure 
via low-salt diet in patients with resistant hypertension 
(5, 27). The reduction of salt intake might therefore be 
as beneficial as reduction of body weight or smoking 
Table 3. Univariate Analyses of the Associations Between 24-Hour Sodium Excretion and Parameters of 
Metabolism and Blood Pressure in All Patients With Primary Aldosteronism
Parameters at 





<0.001 <0.001 0.001 0.001 0.088 0.044 0.542 0.253 0.013 0.028
24-h urinary 
sodium at 1-y 
follow-up, 
mmol/d





<0.001 <0.001 <0.001 0.001 0.917 0.002 0.035 0.004 0.198 <0.001
Data are given as P values. Significance is marked in bold. Correlation analysis was performed using Spearman’s rank-order test.
Abbreviations: 24-h SBP, 24-hour systolic blood pressure; DDD, defined daily doses of antihypertensive medication; FPG, fasting plasma glucose; 
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Figure 3. Changes in 24-hour diastolic blood pressure and proteinuria at 3-year follow-up according to high or low change in 24-hour urinary 
sodium excretion compared with baseline.
Median and 95% confidence interval are shown. *Significance.
Abbreviations: 24-h DBP, 24-hour diastolic blood pressure; Δ 24-h DBP, 24-h DBP at 3-year follow-up—24-h DBP at baseline; Δ Proteinuria, 
proteinuria at 3-year follow-up—proteinuria at baseline.
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cessation for cardiovascular risk (28). In line with these 
findings, Pimenta et al found a correlation between the 
amount of salt intake and the severity of obstructive 
sleep apnea in PA, whereas Takakuwa et  al reported 
of improved nocturnal blood pressure levels following 
dietary sodium restriction (29, 30).
In line with findings from patients with essential 
hypertension, higher sodium intake was associated with 
significantly higher DDD for blood pressure control in 
both unilateral and bilateral PA patients. Additionally, 
there was a positive correlation between the excretion 
of urinary sodium and proteinuria at baseline and at 
follow-up. Decline in urinary sodium excretion at 
follow-up was associated with a decline in proteinuria 
in univariate analysis. Proteinuria itself can be an early 
sign of renal damage representing both organ damage of 
aldosterone excess in PA and as well as an independent 
cardiovascular risk factor (31, 32). Our findings are in 
line with other studies, suggesting an impact of high-
salt diet on cardiovascular risk in PA even after specific 
treatment (33, 34).
Estimated salt intake at baseline was higher in unilat-
eral than in bilateral PA patients (11.9 g/d vs 10.4 g/d). 
Following ADX, estimated daily salt intake was reduced 
from 11.9 g to 10.2 g without any further lifestyle inter-
vention in the unilateral group but remained unchanged 
in the bilateral subgroup treated with MRA. In conjunc-
tion with the findings of He et al (35), who reported a sig-
nificant decrease in cardiovascular events by 20% caused 
by a single reduction of salt intake of about 2 g/d, the 
drop of 1.8 g/d (15%) in the unilateral PA patients is very 
likely of clinical relevance. Catena et al. reported signifi-
cantly greater reduction of left ventricular mass index in 
patients with reduction of urinary sodium excretion after 
treatment of PA (13). In combination with the negative 
impact of increased left ventricular hypertrophy on car-
diovascular risk, this further supports our hypothesis.
In addition to the sodium-retaining function of aldos-
terone, several physiological pathways have been pro-
posed by which aldosterone affects sodium intake. These 
include sodium sensing via the ENaC in the tongue and 
salt appetite regulation in the brain. The ENaC is ex-
pressed in the gustatory system and more precisely in the 
taste buds of the tongue. Although not all mechanisms 
are completely understood, treatment with amiloride is 
known to reduce taste intensity for sodium (36). In ro-
dent studies, mice with ENaC-alpha knockdown in the 
tongue showed almost complete loss of salt attraction in 
contrast to water (37). Pretreatment with high doses of 
deoxycorticosterone, a potent mineralocorticoid, caused 
an increase in saline preference even in ranges, which 
seemed uneatable for untreated rats (38, 39). Sakamoto 
et al. reported lower amiloride-sensitive salt taste nerve 
responses in aldosterone/sodium chloride treated rats, 
which could explain the increase in saline preference and 
consecutively the rise in salt intake (40).
The most popular hypothesis based on evidence from 
rodent studies is that aldosterone is involved in salt ap-
petite via activation of mineralocorticoid receptor in the 
brain and up-regulation of serum- and glucocorticoid-
induced kinase SGK1. Rats injected with aldosterone 
into the cerebral fourth ventricle or the amygdala in-
creased daily salt intake, an effect that could be blocked 
by pretreatment with intracerebroventricular applica-
tion of MRA including spironolactone (41, 42). The 
exact mechanisms still remain uncertain but it was 
interesting to note that salt appetite could not be blocked 
by peripheral application of MRA (43). These findings 
are in accordance with our results and could explain 
why there was no change in salt intake observed in bi-
lateral PA patients after treatment with spironolactone.
In contrast to our findings, Catena et  al found a sig-
nificant decrease of urinary sodium excretion not only 
in a cohort of 30 patients with unilateral PA undergoing 
ADX, but also in 35 bilateral PA patients after 1 year of 
MRA treatment (13). The main difference to their study 
protocol was the higher starting dosage of 50 to 100 mg/d 
for MRA treatment compared with low-dose treatment 
with a starting dose of 25 to 50 mg/d, in accordance with 
Endocrine Society Practice Guidelines (10), in the current 
study. In our patients, dosage escalation was mostly limited 
by side effects including gynecomastia. Dosage at follow-up 
was a median of 50 mg/d in our cohort, contrasted by a 
dosage between 50 and 250  mg/d in the Italian group. 
Unlike Catena et  al., who reinforced their advice to re-
duce sodium intake in close intervals up to the final 1-year 
follow-up, in our center, follow-up visits and nutritional 
counseling were less frequent. In this context, insufficient 
blockade of mineralocorticoid receptors by low-dose MRA 
treatment has to be considered as well as effective lifestyle 
intervention by the Italian group that may explain the con-
troversial results. In summary, PA treatment by ADX seems 
to be more effective in the sustained reduction of salt intake 
and for this reason could be favorable concerning blood 
pressure control and cardiovascular risk.
Our study represents a retrospective analysis of pro-
spectively collected data of patients included in our 
Munich center of the German Conn’s Registry. A limi-
tation in this context is the lack of dietary assessments 
(dietary recall or food frequency questionnaire) to 
evaluate sodium intake. However, dietary assessments 
often deal with difficulties quantifying sodium concen-
tration in different sources as well as underestimation 
in case of social acceptability (44). A minor limitation 
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could be the moderate number of patients fulfilling our 
strict inclusion criteria.
The strengths of our study include the prospective 
standardized collection of all data and biomaterial 
within the context of the German Conn’s Registry. This 
allowed us to include a large number of patients both 
with unilateral and bilateral disease who were adequately 
phenotyped in a standardized fashion and had a 3-year 
follow-up. Furthermore, we used 24-hour urinary so-
dium excretion to estimate dietary salt intake, which 
is considered the gold standard, despite its pitfalls con-
cerning complete 24-hour collection and variability (45).
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